These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
483 related articles for article (PubMed ID: 27189148)
21. Is stimulation of thyroglobulin (Tg) useful in low-risk patients with thyroid carcinoma and undetectable Tg on thyroxin and negative neck ultrasound? Rosário PW; Borges MA; Fagundes TA; Franco AC; Purisch S Clin Endocrinol (Oxf); 2005 Feb; 62(2):121-5. PubMed ID: 15670185 [TBL] [Abstract][Full Text] [Related]
22. Postoperative stimulated thyroglobulin of less than 1 ng/ml as a criterion to spare low-risk patients with papillary thyroid cancer from radioactive iodine ablation. Rosario PW; Mineiro Filho AF; Prates BS; Silva LC; Calsolari MR Thyroid; 2012 Nov; 22(11):1140-3. PubMed ID: 23050786 [TBL] [Abstract][Full Text] [Related]
23. Lymph node status influences follow-up thyroglobulin levels in papillary thyroid cancer. Low TH; Delbridge L; Sidhu S; Learoyd D; Robinson B; Roach P; Sywak M Ann Surg Oncol; 2008 Oct; 15(10):2827-32. PubMed ID: 18636294 [TBL] [Abstract][Full Text] [Related]
24. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation. Barbaro D; Boni G; Meucci G; Simi U; Lapi P; Orsini P; Pasquini C; Piazza F; Caciagli M; Mariani G J Clin Endocrinol Metab; 2003 Sep; 88(9):4110-5. PubMed ID: 12970272 [TBL] [Abstract][Full Text] [Related]
25. Disease outcomes and nodal recurrence in patients with papillary thyroid cancer and lateral neck nodal metastases. O'Neill CJ; Coorough N; Lee JC; Clements J; Delbridge LW; Sippel R; Sywak MS; Chen H; Sidhu SB ANZ J Surg; 2014 Apr; 84(4):240-4. PubMed ID: 23316684 [TBL] [Abstract][Full Text] [Related]
26. Serum thyroglobulin level measured after thyroxine withdrawal is useful to predict further recurrence in whole body scan-negative papillary thyroid cancer patients after reoperation. Park DJ; Lim JA; Kim TH; Choi HS; Ahn HY; Lee EK; Lee YJ; Kim KW; Park YJ; Yi KH; Cho BY Endocr J; 2012; 59(11):1021-30. PubMed ID: 22814366 [TBL] [Abstract][Full Text] [Related]
27. Low thyroglobulin concentrations after thyroidectomy increase the prognostic value of undetectable thyroglobulin levels on levo-thyroxine suppressive treatment in low-risk differentiated thyroid cancer. Piccardo A; Arecco F; Morbelli S; Bianchi P; Barbera F; Finessi M; Corvisieri S; Pestarino E; Foppiani L; Villavecchia G; Cabria M; Orlandi F J Endocrinol Invest; 2010 Feb; 33(2):83-7. PubMed ID: 19636213 [TBL] [Abstract][Full Text] [Related]
28. Changes in Serum Thyroglobulin Levels After Lobectomy in Patients with Low-Risk Papillary Thyroid Cancer. Park S; Jeon MJ; Oh HS; Lee YM; Sung TY; Han M; Han JM; Kim TY; Chung KW; Kim WB; Shong YK; Kim WG Thyroid; 2018 Aug; 28(8):997-1003. PubMed ID: 29845894 [TBL] [Abstract][Full Text] [Related]
29. Recombinant human thyroid-stimulating hormone (Thyrogen) in thyroid cancer follow up: experience at a single institution. Wong R; Topliss DJ; Bach LA; Hamblin PS; Kalff V; Long F; Stockigt JR Intern Med J; 2009 Mar; 39(3):156-63. PubMed ID: 19383064 [TBL] [Abstract][Full Text] [Related]
30. Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma. Pacini F; Molinaro E; Lippi F; Castagna MG; Agate L; Ceccarelli C; Taddei D; Elisei R; Capezzone M; Pinchera A J Clin Endocrinol Metab; 2001 Dec; 86(12):5686-90. PubMed ID: 11739420 [TBL] [Abstract][Full Text] [Related]
31. A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. Mazzaferri EL; Robbins RJ; Spencer CA; Braverman LE; Pacini F; Wartofsky L; Haugen BR; Sherman SI; Cooper DS; Braunstein GD; Lee S; Davies TF; Arafah BM; Ladenson PW; Pinchera A J Clin Endocrinol Metab; 2003 Apr; 88(4):1433-41. PubMed ID: 12679418 [TBL] [Abstract][Full Text] [Related]
32. Preoperative undetectable serum thyroglobulin in differentiated thyroid carcinoma: incidence, causes and management strategy. Giovanella L; Ceriani L; Ghelfo A; Maffioli M; Keller F Clin Endocrinol (Oxf); 2007 Oct; 67(4):547-51. PubMed ID: 17561976 [TBL] [Abstract][Full Text] [Related]
33. Patients with Papillary Thyroid Carcinoma at Intermediate Risk of Recurrence According to American Thyroid Association Criteria Can Be Reclassified as Low Risk When the Postoperative Thyroglobulin Is Low. Rosario PW; Furtado Mde S; Mourão GF; Calsolari MR Thyroid; 2015 Nov; 25(11):1243-8. PubMed ID: 26359309 [TBL] [Abstract][Full Text] [Related]
34. Transient early increase in thyroglobulin levels post-radioiodine ablation in patients with differentiated thyroid cancer. Stevic I; Dembinski TC; Pathak KA; Leslie WD Clin Biochem; 2015 Jul; 48(10-11):658-61. PubMed ID: 25895485 [TBL] [Abstract][Full Text] [Related]
35. Follow-up of differentiated thyroid carcinoma. Pagano L; Klain M; Pulcrano M; Angellotti G; Pasano F; Salvatore M; Lombardi G; Biondi B Minerva Endocrinol; 2004 Dec; 29(4):161-74. PubMed ID: 15765026 [TBL] [Abstract][Full Text] [Related]
36. Serum Basal thyroglobulin measured by a second-generation assay correlates with the recombinant human thyrotropin-stimulated thyroglobulin response in patients treated for differentiated thyroid cancer. Spencer C; Fatemi S; Singer P; Nicoloff J; Lopresti J Thyroid; 2010 Jun; 20(6):587-95. PubMed ID: 20470203 [TBL] [Abstract][Full Text] [Related]
37. Thyroglobulin assay during thyroxine treatment in low-risk differentiated thyroid cancer management: comparison with recombinant human thyrotropin-stimulated assay and imaging procedures. Giovanella L; Ceriani L; Ghelfo A; Keller F; Sacchi A; Maffioli M; Spriano G Clin Chem Lab Med; 2006; 44(5):648-52. PubMed ID: 16681439 [TBL] [Abstract][Full Text] [Related]
38. Impact of cervical lymph node dissection on serum TG and the course of disease in TG-positive, radioactive iodine whole body scan-negative recurrent/persistent papillary thyroid cancer. Alzahrani AS; Raef H; Sultan A; Al Sobhi S; Ingemansson S; Ahmed M; Al Mahfouz A J Endocrinol Invest; 2002 Jun; 25(6):526-31. PubMed ID: 12109624 [TBL] [Abstract][Full Text] [Related]
39. Is TSH suppression still necessary in intermediate- and high-risk papillary thyroid cancer patients with pre-ablation stimulated thyroglobulin <1 ng/mL before the first disease assessment? Tian T; Huang R; Liu B Endocrine; 2019 Jul; 65(1):149-154. PubMed ID: 30924085 [TBL] [Abstract][Full Text] [Related]
40. Reoperative lymph node dissection for recurrent papillary thyroid cancer and effect on serum thyroglobulin. Hughes DT; Laird AM; Miller BS; Gauger PG; Doherty GM Ann Surg Oncol; 2012 Sep; 19(9):2951-7. PubMed ID: 22526913 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]